Berberine and visceral fat reduction is an area of growing scientific interest, with emerging evidence suggesting this plant-derived alkaloid may offer modest benefits for abdominal adiposity and metabolic health. Berberine, extracted from plants such as barberry and goldenseal, activates the enzyme AMPK — a key regulator of energy metabolism — and has been studied for its effects on blood glucose, lipid profiles, and body composition. In the UK, berberine is sold as a food supplement rather than a licensed medicine. This article explores the evidence, safety considerations, drug interactions, and how berberine fits within a broader, NHS-aligned approach to managing visceral fat.

What Is Berberine and How Does It Work in the Body?

Berberine is a plant-derived alkaloid that primarily works by activating AMPK, promoting glucose uptake and fatty acid oxidation while inhibiting fat synthesis. In the UK it is sold as an unregulated food supplement, not a licensed medicine.

Berberine is a naturally occurring alkaloid extracted from several plants, including barberry (Berberis vulgaris), goldenseal, and tree turmeric. It has been used for centuries in traditional Chinese and Ayurvedic medicine, primarily for its antimicrobial and anti-inflammatory properties. In recent years, it has attracted considerable scientific interest for its potential metabolic effects, particularly in relation to blood glucose regulation, lipid metabolism, and body composition.

At a cellular level, berberine's primary mechanism of action involves the activation of AMP-activated protein kinase (AMPK), an enzyme that plays a central role in regulating energy balance within cells. When activated, AMPK promotes glucose uptake, enhances fatty acid oxidation, and inhibits fat synthesis (lipogenesis).^[10][5] Berberine shares this AMPK-activating pathway with metformin, though the two differ substantially in their evidence base, pharmacokinetics, regulatory status, and clinical applications — they should not be considered equivalent.^[10][5]

Berberine also appears to influence the gut microbiome, modulating the composition of intestinal bacteria in ways that may support metabolic health, though much of this evidence remains preliminary. Additionally, it has demonstrated effects on insulin sensitivity, reducing fasting blood glucose and improving lipid profiles in several clinical studies.

It is worth noting that berberine has poor oral bioavailability and is subject to significant first-pass metabolism.^[3][4] It is also a known inhibitor of cytochrome P450 enzymes (particularly CYP3A4 and CYP2D6) and P-glycoprotein (P-gp), which has important implications for drug interactions (discussed further below).

In the UK, berberine is available as a food supplement — typically in capsule form — and is not licensed as a medicine by the Medicines and Healthcare products Regulatory Agency (MHRA) for any specific clinical indication.^[6][7] UK food supplements are regulated under food law, overseen by the Food Standards Agency (FSA) and local authorities, rather than by the MHRA. Typical product doses range from 500 mg to 1,500 mg daily, but consumers should follow the manufacturer's label and seek advice from a GP or pharmacist before starting supplementation.

The Link Between Berberine and Visceral Fat Reduction

Meta-analyses show berberine is associated with modest, statistically significant reductions in waist circumference and BMI, most consistently in people with existing metabolic dysregulation such as obesity or type 2 diabetes.

Visceral fat — the metabolically active fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas, and intestines — is strongly associated with increased risk of type 2 diabetes, cardiovascular disease, and metabolic syndrome. Unlike subcutaneous fat (found just beneath the skin), visceral fat is particularly responsive to hormonal and metabolic signals, making it a key target in metabolic health interventions.

In the UK, clinical thresholds for central adiposity include a waist circumference of 94 cm or above in men and 80 cm or above in women as indicators of increased cardiometabolic risk, with higher thresholds (102 cm and 88 cm respectively) indicating substantially increased risk (NICE CG189). Individuals meeting these thresholds are encouraged to seek clinical assessment.

Several clinical trials and meta-analyses have investigated berberine's effects on body composition and metabolic markers. A meta-analysis published in Phytomedicine found that berberine supplementation was associated with statistically significant reductions in waist circumference and body mass index (BMI) compared to placebo.^[12][13] Some imaging-based studies have also reported reductions in abdominal adiposity, though the majority of trials rely on surrogate measures such as waist circumference rather than direct imaging of visceral fat area. Effect sizes are generally modest, and findings are most consistent in people with existing metabolic dysregulation.

The proposed mechanisms include:

• Reduced lipogenesis: By activating AMPK, berberine suppresses enzymes responsible for converting excess glucose into stored fat.

• Improved insulin sensitivity: Lower circulating insulin levels reduce the stimulus for visceral fat accumulation.

• Gut microbiome modulation: Some studies suggest berberine may increase populations of bacteria such as Akkermansia muciniphila, which are associated with reduced adiposity and improved metabolic function — though this evidence is preliminary and heterogeneous in human studies.^[15]

• Reduced inflammation: Berberine has demonstrated anti-inflammatory properties that may help interrupt the cycle of visceral fat-driven systemic inflammation.

Most studies have been conducted in populations with obesity, metabolic syndrome, or type 2 diabetes, and many trials are of relatively short duration. Larger, long-term randomised controlled trials in broader populations are needed before definitive clinical recommendations can be made. The current evidence suggests a modest but potentially meaningful effect on abdominal adiposity when berberine is used alongside dietary and lifestyle modifications.

Safety, Side Effects, and UK Regulatory Guidance on Berberine

The most common side effects are gastrointestinal — including nausea, diarrhoea, and bloating — and berberine carries significant drug interaction risks via CYP3A4, CYP2D6, and P-gp inhibition, particularly with warfarin, statins, and glucose-lowering medicines.

Berberine is generally considered well tolerated at commonly used doses, but it is not without potential adverse effects. The most frequently reported side effects are gastrointestinal in nature and include:

• Nausea and stomach discomfort

• Diarrhoea or constipation

• Bloating and flatulence

• Abdominal cramping

These effects are typically dose-dependent and often improve when berberine is taken with food or when the dose is started low and gradually increased. Dividing the daily dose into two or three smaller amounts throughout the day may also help minimise gastrointestinal symptoms.

If you experience a suspected side effect from berberine or any other supplement, you can report it to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

From a regulatory standpoint, berberine supplements in the UK are regulated under food law by the FSA and local authorities — not by the MHRA, which regulates licensed medicines.^[7][8] This means that quality, purity, and dosage consistency can vary considerably between brands. Consumers are advised to choose products with third-party quality certification and to purchase from reputable suppliers.

A significant safety concern relates to berberine's potential for drug interactions. Berberine inhibits CYP3A4, CYP2D6, and P-glycoprotein (P-gp), which can affect the metabolism and plasma concentrations of a wide range of medicines.^[1][2] Clinically important interactions include:

• Insulin and sulfonylureas (e.g., gliclazide, glibenclamide) — additive glucose-lowering effects increase the risk of hypoglycaemia; blood glucose monitoring is essential and prescribed doses should not be altered without medical advice. Note that metformin alone rarely causes hypoglycaemia, but combination use still warrants caution.

• Anticoagulants such as warfarin — berberine may affect INR; evidence is limited but INR monitoring is advisable.

• Narrow-therapeutic-index medicines — including digoxin, ciclosporin, and tacrolimus, where altered drug levels could have serious consequences.

• Certain statins (e.g., simvastatin, atorvastatin) — P-gp and CYP3A4 inhibition may increase statin exposure and the risk of adverse effects such as myopathy.

• Some antibiotics and immunosuppressants.

For a comprehensive assessment of potential interactions, consult a pharmacist or GP, or refer to an authoritative interaction resource such as Stockley's Herbal Medicines Interactions (Pharmaceutical Press).

Berberine is contraindicated in pregnancy and breastfeeding. Animal and limited human data suggest potential harm to the foetus and neonate, including a theoretical risk of neonatal hyperbilirubinaemia (kernicterus). UK resources such as the UK Teratology Information Service (UKTIS) and Specialist Pharmacy Service (SPS) can provide further guidance. Anyone taking prescribed medication or managing a chronic health condition should consult their GP or pharmacist before starting berberine supplementation.

Who May Benefit and Who Should Exercise Caution

Adults with metabolic syndrome, prediabetes, or type 2 diabetes show the most consistent benefit, while berberine is contraindicated in pregnancy and requires medical supervision in those taking insulin, sulfonylureas, or narrow-therapeutic-index medicines.

The available evidence suggests that certain groups may derive the most benefit from berberine supplementation in the context of visceral fat and metabolic health. Adults with metabolic syndrome, prediabetes, type 2 diabetes, or non-alcoholic fatty liver disease (NAFLD) — now increasingly termed metabolic dysfunction-associated steatotic liver disease (MASLD) in UK clinical practice — appear to show the most consistent improvements in metabolic markers and body composition in clinical studies. Individuals with elevated fasting glucose, raised triglycerides, or a high waist circumference — all markers of excess visceral adiposity — may find berberine a useful adjunct to lifestyle modification.

However, several groups should exercise particular caution or avoid berberine altogether:

• Pregnant or breastfeeding women: Berberine is contraindicated due to potential neonatal harm, including risk of hyperbilirubinaemia.

• Children and adolescents: There is insufficient safety data to support use in this population.

• Individuals taking insulin or sulfonylureas: Additive glucose-lowering effects increase the risk of hypoglycaemia; medical supervision is essential.^[17][18]

• Individuals on anticoagulant therapy (e.g., warfarin): Close monitoring of clotting parameters is advisable.

• People taking narrow-therapeutic-index medicines such as digoxin, ciclosporin, or tacrolimus: Berberine's inhibition of CYP3A4/CYP2D6 and P-gp may significantly alter drug levels.

• People with liver or kidney impairment: Altered drug metabolism may increase the risk of adverse effects.

It is important to emphasise that berberine is not a substitute for evidence-based medical treatment. NICE guidelines for type 2 diabetes (NICE NG28), NAFLD/MASLD (NICE NG49), lipid modification and cardiovascular risk (NICE NG238), and obesity management (NICE CG189) are built upon robust clinical trial data, and berberine should not replace prescribed therapies. Patients interested in berberine should discuss this openly with their GP or pharmacist, particularly if they are managing any long-term condition, to ensure it is appropriate and safe within their overall care plan.

Lifestyle Approaches Alongside Berberine for Visceral Fat

Berberine's effects on visceral fat are most meaningful when combined with a Mediterranean-style diet, at least 150 minutes of moderate-intensity exercise per week per UK CMO guidelines, and attention to sleep and stress management.

Berberine is not a standalone solution for visceral fat reduction, and the evidence consistently shows that its effects are most meaningful when combined with sustained lifestyle changes. NICE guidance on weight management and metabolic health (NICE CG189) emphasises a whole-person approach, incorporating dietary modification, physical activity, sleep hygiene, and stress management.

Dietary strategies that complement berberine's mechanisms include:

• Reducing ultra-processed foods and refined carbohydrates, which drive insulin spikes and promote visceral fat storage.

• Adopting a Mediterranean-style diet rich in vegetables, legumes, whole grains, oily fish, and healthy fats — a pattern consistently associated with reduced visceral adiposity. The NHS Eatwell Guide provides practical, patient-facing dietary guidance aligned with UK recommendations.

• Limiting alcohol intake, as alcohol is directly linked to hepatic and visceral fat accumulation.

• Ensuring adequate dietary fibre to support gut microbiome health.

Physical activity is one of the most effective interventions for visceral fat specifically. Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training have been shown to reduce visceral fat independently of weight loss.^[24][25] The UK Chief Medical Officers' Physical Activity Guidelines (2019) recommend at least 150 minutes of moderate-intensity activity (or 75 minutes of vigorous-intensity activity) per week, alongside muscle-strengthening activities on two or more days per week.

Sleep and stress management are often overlooked but are critically important. Poor sleep and chronic psychological stress elevate cortisol levels, which directly promotes visceral fat deposition. Addressing sleep quality and incorporating stress-reduction techniques such as mindfulness or cognitive behavioural strategies can meaningfully support metabolic health.

Individuals with a waist circumference above the UK risk thresholds (94 cm or above in men; 80 cm or above in women), or those experiencing symptoms such as unexplained thirst, fatigue, or frequent urination, should seek a clinical assessment to evaluate cardiometabolic risk before relying on supplementation alone.

In summary, berberine and visceral fat reduction is an area of genuine scientific interest, with a growing body of evidence supporting a modest beneficial effect on abdominal adiposity, particularly in people with metabolic dysregulation. However, berberine should be viewed as one component of a broader, evidence-informed lifestyle strategy rather than a quick fix. Anyone considering berberine is encouraged to seek personalised advice from a qualified healthcare professional — their GP or pharmacist — before starting supplementation.

Frequently Asked Questions